Targeted α-therapy using astatine ( 211 At)-labeled PSMA1, 5, and 6: a preclinical evaluation as a novel compound.

Tadashi WatabeKazuko Kaneda-NakashimaYoshifumi ShirakamiYuichiro KadonagaKazuhiro OoeYang WangHiromitsu HabaAtsushi ToyoshimaJens CardinaleFrederik L GieselNoriyuki TomiyamaKoichi Fukase

Published in: European journal of nuclear medicine and molecular imaging (2022)

At]PSMA5 should be considered a new possible TAT for metastatic CRPC, and translational prospective trials are warranted.

Keyphrases

pet imaging
pet ct
squamous cell carcinoma
small cell lung cancer
positron emission tomography
cell therapy
stem cells